Literature DB >> 31273504

The Self-Efficacy to Communicate about Sex and Intimacy (SECSI) scale: psychometric assessment in women treated for cancer.

Elizabeth K Arthur1, Celia E Wills2, Kristine Browning2, Janine Overcash2, Usha Menon3.   

Abstract

PURPOSE: The purpose of this study was to conduct a preliminary validation of the psychometric performance of the newly developed Self-Efficacy to Communicate about Sex and Intimacy (SECSI) scale in a sample of women treated for cancer.
METHODS: Partnered women (n = 250) who had received treatment for cancer completed an online survey that included the SECSI scale and measures of health-related quality of life, depression, anxiety, sexual function, sexual distress, self-efficacy for sexual functioning, sexual behaviors, relationship satisfaction, and satisfaction with sexual communication. Sociodemographic and clinical cancer characteristics data were collected.
RESULTS: High internal consistency and strong test-retest reliability of the SECSI scale were shown with a Cronbach's alpha coefficient of 0.94 and test-retest reliability of r = 0.82, respectively. Construct validity of the SECSI scale, including discriminant, convergent, and divergent validity, was supported except regarding hypothesized relationships between SECSI scores and participant age and time since treatment.
CONCLUSIONS: The SECSI scale is a valid, reliable measure for use with partnered women treated for cancer. Clinicians working with cancer survivors who may be at risk for difficulties communicating about sex and intimacy needs after cancer treatment may use this scale to identify women who would benefit from interventions to increase their confidence to communicate with their partner. The SECSI scale fills an important gap in ability to assess self-efficacy to communicate about sex and intimacy.

Entities:  

Keywords:  Cancer; Intimacy; Partner communication; Self-efficacy; Sexual function

Mesh:

Year:  2019        PMID: 31273504     DOI: 10.1007/s00520-019-04963-2

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  35 in total

1.  The Female Sexual Function Index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function.

Authors:  R Rosen; C Brown; J Heiman; S Leiblum; C Meston; R Shabsigh; D Ferguson; R D'Agostino
Journal:  J Sex Marital Ther       Date:  2000 Apr-Jun

2.  Sexual morbidity in very long term survivors of vaginal and cervical cancer: a comparison to national norms.

Authors:  Stacy Tessler Lindau; Natalia Gavrilova; Diane Anderson
Journal:  Gynecol Oncol       Date:  2007-06-20       Impact factor: 5.482

Review 3.  Sexual (dys)function and the quality of sexual life in patients with colorectal cancer: a systematic review.

Authors:  M J Traa; J De Vries; J A Roukema; B L Den Oudsten
Journal:  Ann Oncol       Date:  2011-04-20       Impact factor: 32.976

4.  A brief measure for assessing generalized anxiety disorder: the GAD-7.

Authors:  Robert L Spitzer; Kurt Kroenke; Janet B W Williams; Bernd Löwe
Journal:  Arch Intern Med       Date:  2006-05-22

5.  General population and cancer patient norms for the Functional Assessment of Cancer Therapy-General (FACT-G).

Authors:  Penny S Brucker; Kathleen Yost; John Cashy; Kimberly Webster; David Cella
Journal:  Eval Health Prof       Date:  2005-06       Impact factor: 2.651

6.  Dyadic sexual communication in pre-menopausal women with self-reported dyspareunia and their partners: associations with sexual function, sexual distress and dyadic adjustment.

Authors:  Els Pazmany; Sophie Bergeron; Johan Verhaeghe; Lukas Van Oudenhove; Paul Enzlin
Journal:  J Sex Med       Date:  2014-12-05       Impact factor: 3.802

7.  The risk of being depressed is significantly higher in cancer patients than in the general population: Prevalence and severity of depressive symptoms across major cancer types.

Authors:  T J Hartung; E Brähler; H Faller; M Härter; A Hinz; C Johansen; M Keller; U Koch; H Schulz; J Weis; A Mehnert
Journal:  Eur J Cancer       Date:  2016-12-23       Impact factor: 9.162

8.  Psychometric validation of the Female Sexual Function Index (FSFI) in cancer survivors.

Authors:  Raymond E Baser; Yuelin Li; Jeanne Carter
Journal:  Cancer       Date:  2012-02-22       Impact factor: 6.860

Review 9.  Physical and psychological effects of treatment on sexual functioning in colorectal cancer survivors.

Authors:  Stephanie O Breukink; Kristine A Donovan
Journal:  J Sex Med       Date:  2013-02       Impact factor: 3.802

10.  The association between psychosocial and medical factors with long-term sexual dysfunction after treatment for colorectal cancer.

Authors:  Kathrin Milbury; Lorenzo Cohen; Rosell Jenkins; John M Skibber; Leslie R Schover
Journal:  Support Care Cancer       Date:  2012-09-05       Impact factor: 3.603

View more
  3 in total

1.  Prevalence and predictors of poor sexual well-being over 5 years following treatment for colorectal cancer: results from the ColoREctal Wellbeing (CREW) prospective longitudinal study.

Authors:  Jane Frankland; Sally Wheelwright; Natalia V Permyakova; David Wright; Nicole Collaço; Lynn Calman; Jane Winter; Deborah Fenlon; Alison Richardson; Peter W Smith; Claire Foster
Journal:  BMJ Open       Date:  2020-11-12       Impact factor: 2.692

2.  Profiles of women's adjustment after cancer based on sexual and psychosocial wellbeing: results of a cluster analysis.

Authors:  Elizabeth K Arthur; Usha Menon; Jennifer Barsky Reese; Kristine Browning; Janine Overcash; Karen Rose; Celia E Wills
Journal:  BMC Cancer       Date:  2022-09-21       Impact factor: 4.638

3.  Opening the Conversation: study protocol for a Phase III trial to evaluate a couple-based intervention to reduce reproductive and sexual distress among young adult breast and gynecologic cancer survivor couples.

Authors:  Jessica R Gorman; Karen S Lyons; S Marie Harvey; Chiara Acquati; John M Salsman; Deborah A Kashy; Julia H Drizin; Ellie Smith; Lisa M Flexner; Brandon Hayes-Lattin; Jennifer B Reese
Journal:  Trials       Date:  2022-09-02       Impact factor: 2.728

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.